- Home
- LXEO vs LYEL Comparison
LXEO vs LYEL Comparison
Compare LXEO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- LYEL
- Stock Information
- Founded
- LXEO 2017
- LYEL 2018
- Country
- LXEO United States
- LYEL United States
- Employees
- LXEO N/A
- LYEL N/A
- Industry
- LXEO
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- LYEL Health Care
- Exchange
- LXEO Nasdaq
- LYEL Nasdaq
- Market Cap
- LXEO 290.5M
- LYEL 253.2M
- IPO Year
- LXEO 2023
- LYEL 2021
- Fundamental
- Price
- LXEO $6.47
- LYEL $17.85
- Analyst Decision
- LXEO Strong Buy
- LYEL Hold
- Analyst Count
- LXEO 7
- LYEL 3
- Target Price
- LXEO $15.29
- LYEL $16.67
- AVG Volume (30 Days)
- LXEO 763.8K
- LYEL 67.2K
- Earning Date
- LXEO 11-12-2025
- LYEL 11-06-2025
- Dividend Yield
- LXEO N/A
- LYEL N/A
- EPS Growth
- LXEO N/A
- LYEL N/A
- EPS
- LXEO N/A
- LYEL N/A
- Revenue
- LXEO N/A
- LYEL $60,000.00
- Revenue This Year
- LXEO N/A
- LYEL N/A
- Revenue Next Year
- LXEO N/A
- LYEL N/A
- P/E Ratio
- LXEO N/A
- LYEL N/A
- Revenue Growth
- LXEO N/A
- LYEL 11.11
- 52 Week Low
- LXEO $1.45
- LYEL $7.65
- 52 Week High
- LXEO $11.72
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- LXEO 67.21
- LYEL 76.65
- Support Level
- LXEO $6.33
- LYEL $15.62
- Resistance Level
- LXEO $6.90
- LYEL $17.45
- Average True Range (ATR)
- LXEO 0.51
- LYEL 1.03
- MACD
- LXEO 0.05
- LYEL 0.43
- Stochastic Oscillator
- LXEO 62.04
- LYEL 92.87
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.